Company Monitoring Page for Alnylam

latest headlines for company on cafepharma

Alnylam Snaps Up Merck’s Sirna Therapeutics
Wall St Cheat Sheet
Mon, 01/13/14 - 02:51 pm
Tags:
siRNA, M&A, Merck, Alnylam, RNAi
The J.P. Morgan Healthcare Confab Monday Morning News Dump
TheStreet.com
Mon, 01/13/14 - 10:12 am
Tags:
JPMHC 2014, GSK, Intercept Pharma, Acorda Therapeutics, Cell Therapeutics, Novartis, Sanofi, Alnylam, Idenix, Alexion, Galena Biopharma, Incyte, Clovis Oncology, Dendreon, Merck, Arena Pharmaceuticals
Sanofi Pays $700 Million for Alnylam Drugs and Stake
Bloomberg
Mon, 01/13/14 - 08:47 am
Tags:
Sanofi, Alnylam, Patisiran
Alnylam Pharmaceuticals, Inc.: The Best Performing Biotechs of 2013
Motley Fool
Thu, 12/26/13 - 01:52 pm
Tags:
RNAi, Alnylam
Alnylam Pharmaceuticals, Inc.: The Best Performing Biotechs of 2013
Motley Fool
Thu, 12/26/13 - 01:51 pm
Tags:
Alnylam, RNAi
Biggest Winners in Biotech This Year
Motley Fool
Tue, 12/10/13 - 09:14 am
Tags:
Acadia, Puma Biotechnology, Alnylam, Celldex Therapeutics
Alnylam earns $7M payment for patisiran Phase II 'success'
The Fly on the Wall
Mon, 11/25/13 - 10:44 am
Tags:
Alnylam, Patisiran, Genzyme, Sanofi
Alnylam rises as FDA bestows fast-track status
Yahoo/AP
Mon, 11/11/13 - 02:13 pm
Tags:
fast track, Alnylam, FDA, Patisiran
Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial
Yahoo/BusinessWire
Sun, 11/10/13 - 01:08 pm
Tags:
Alnylam, Patisiran, amyloidosis, TTR-mediated amyloidosis
Alnylam 4Q loss widens on fewer drug partnerships
Yahoo/AP
Thu, 11/7/13 - 08:13 am
Tags:
Alnylam, earnings
This New Cholesterol Treatment Has Blockbuster Potential
Motley Fool
Tue, 10/15/13 - 10:09 am
Tags:
Alnylam, gene silencing, Pfizer, statins, ALN-PCS
Alnylam advances Development Candidate for ALN-AS1
Yahoo/Fly on the Wall
Tue, 10/8/13 - 08:43 am
Tags:
Alnylam, ALN-AS1, hepatic porphyrias
New Type of Drug to Lower LDL Looks Promising
Med Page Today
Thu, 10/3/13 - 11:33 am
Tags:
LDL cholesterol, Alnylam, PCSK9 inhibitors
Alnylam's Biggest Opportunities
Motley Fool
Wed, 10/2/13 - 10:02 am
Tags:
Alnylam, RNAi, ATTR, hemophilia, porphyria
3 Promising Stocks Targeting CTGF and Dermal Scarring
Wall St Cheat Sheet
Sat, 09/14/13 - 10:56 am
Tags:
dermal scarring, RXI-109, Alnylam, Pfizer, RXi Pharmaceuticals, EXC-001, ALN-TTR02
Alnylam Targets New Highs On Data Supporting RNAi
Seeking Alpha
Sat, 07/20/13 - 11:18 am
Tags:
RNA interference, Alnylam
The Best- And Worst-Performing Biotech Stocks July 5 To July 12
Forbes
Mon, 07/15/13 - 11:21 am
Tags:
Vivus, Trius Therapeutics, Prosensa, Pharmacyclics, NxStage Medical, Natus Medical, MiMedx, Merrimack Pharmaceuticals, Intuitive Surgical, InterMune, GTx, Fluidigm, Epizyme, Celldex, Astex, Analogic, Amarin, Alnylam, Alexion, AcelRx
This Week in Biotech
Motley Fool
Sun, 07/14/13 - 11:19 am
Tags:
Pharmacyclics, JNJ, Alnylam, Inovio, Alexion, Roche
3 Humongous Health-Care Stocks This Week
Motley Fool
Sat, 07/13/13 - 11:46 am
Tags:
Prosensa, Alnylam, Web MD
Alnylam Soars To New High On Early Drug Trial Results
Investors.com
Fri, 07/12/13 - 07:32 am
Tags:
Alnylam, RNAi, ALN-TTRsc

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.